LSCIBP
LSCIBC
Overview
LSCIBP
67
Components
$5.6B
Median Mkt Cap
(as of 6/30/2026)
(as of 6/30/2026)
Equal
Weighting
Semi-Annual
Reconstitution
LSCIBP Index Performance
Past performance is not indicative of future results. One cannot invest directly in an index. Source: LifeSci Index Partners / Indxx, Inc.
What Is LSCIBP?
The LifeSci Biotechnology Products Index tracks U.S.-listed pure biotechnology companies that have at least one FDA-approved drug therapy generating commercial revenue. With 67 components at equal weight, LSCIBP provides diversified exposure to the proven, revenue-generating segment of the biotech sector.
When to Use LSCIBP
LSCIBP is designed for investors seeking exposure to commercial-stage biotechnology — companies with validated products, recurring revenue, and reimbursement visibility. It serves as a complement to broad healthcare allocations or as a targeted biotech sleeve.
Representative Holdings as of 6/30/2026
| Ticker | Company | Category |
|---|---|---|
| Large Cap | ||
| AMGN | Amgen Inc. | Large Cap |
| GILD | Gilead Sciences | Large Cap |
| VRTX | Vertex Pharmaceuticals | Large Cap |
| Mid Cap | ||
| LGND | Ligand Pharmaceuticals | Mid Cap |
| LEGN | Legend Biotech | Mid Cap |
| TVTX | TG Therapeutics | Mid Cap |
| Small Cap | ||
| IRWD | Ironwood Pharmaceuticals | Small Cap |
| OMER | Omeros Corporation | Small Cap |
| VSTM | Verastem Inc. | Small Cap |